PREDSULFAIR II
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREDSULFAIR II (PREDSULFAIR II).
Prednisolone is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators. Sulfonamide component provides bacteriostatic action via inhibition of dihydropteroate synthase in bacterial folate synthesis.
| Metabolism | Primarily hepatic via CYP3A4; prednisolone is the active metabolite of prednisone. Sulfonamide is metabolized via N-acetylation and glucuronidation. |
| Excretion | Renal: 70-80% (30-50% as unchanged prednisolone, 20-30% as prednisone and inactive metabolites); Biliary/Fecal: 15-20% |
| Half-life | Terminal elimination half-life of prednisolone (active moiety): 2.1-3.5 hours; clinical context: duration of HPA axis suppression exceeds plasma half-life (12-36 hours). |
| Protein binding | Prednisolone: 70-90% bound to corticosteroid-binding globulin (CBG) and albumin; binding is concentration-dependent and saturable. |
| Volume of Distribution | Prednisolone: 0.4-1.0 L/kg; indicates extensive tissue penetration and distribution into total body water. |
| Bioavailability | Oral prednisolone: 70-90%; Oral prednisone: 60-80% (hepatic conversion to prednisolone); Ophthalmic: minimal systemic absorption (<1%) with standard dosing. |
| Onset of Action | Intravenous: 1-2 hours for peak anti-inflammatory effect; Oral: 1-4 hours; Topical: minutes to hours for dermatologic effects; Ophthalmic: 1-2 hours for intraocular inflammation reduction. |
| Duration of Action | Plasma adrenal suppression: 24-36 hours after single dose; anti-inflammatory effect persists for 12-36 hours; duration varies with dose and route. |
| Molecular Weight | Prednisolone: 360.44 Da; Sulfacetamide: 214.25 Da; combination product: Not applicable. |
1-2 drops into the affected eye(s) every 4-6 hours; not to exceed 6 doses per day.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No specific adjustment recommended; systemic absorption is minimal. |
| Liver impairment | No specific adjustment recommended; systemic absorption is minimal. |
| Pediatric use | Not recommended for use in children under 2 years of age. For children ≥2 years, same as adult dosing. |
| Geriatric use | No specific adjustment required; use with caution due to potential increased intraocular pressure risk. |
| 1st trimester | Contains prednisolone (category C) and sulfacetamide (category C). Prednisolone: increased risk of cleft palate if used in first trimester. Sulfacetamide: theoretical risk of kernicterus due to bilirubin displacement; avoid near term. Use only if maternal benefit outweighs fetal risk. |
| 2nd trimester | Prednisolone: possible intrauterine growth restriction with prolonged use. Sulfacetamide: as in t1, theoretical risk of kernicterus. Use lowest effective dose. |
| 3rd trimester | Prednisolone: neonatal adrenal suppression if maternal doses > 20 mg/day for > 3 weeks; monitor neonate. Sulfacetamide: avoid near term due to bilirubin displacement risk; use alternative if possible. |
Clinical note
Comprehensive clinical and safety monograph for PREDSULFAIR II (PREDSULFAIR II).
| Placental transfer | Prednisolone is metabolized to prednisone; both cross placenta, but placental 11β-HSD2 converts most to inactive cortisone, limiting fetal exposure. Sulfacetamide crosses placenta; at term, can displace bilirubin and theoretically cause kernicterus. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to prednisolone, sulfacetamide, or any componentSulfonamide hypersensitivityActive ocular herpes simplex (dendritic keratitis)Fungal or viral infections of the eye (except acute herpetic keratitis)Vaccinia, varicella, and most other viral diseases of the cornea and conjunctivaMycobacterial ocular infectionsThinning of the cornea or sclera (risk of perforation)
| Precautions | Prolonged use may cause immunosuppression, delayed wound healing, and secondary infections. Sulfonamides may cause hypersensitivity reactions, keratoconjunctivitis sicca, and blood dyscrasias. Use with caution in animals with diabetes, renal impairment, or hepatic disease. |
| Food/Dietary | No significant food interactions; however, alcohol may increase the risk of gastric irritation from prednisolone. Take with food or milk to reduce gastrointestinal upset. |
Loading safety data…
| Breastfeeding |
| Prednisolone enters breast milk in low levels (<0.1% of maternal dose); considered compatible with breastfeeding at moderate doses. Sulfacetamide is poorly absorbed orally; minimal systemic exposure for infant. However, observe for possible diarrhea or rash in infant. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Class C - potential risk based on animal studies with prednisolone; sulfacetamide not assessed. Second/third trimester: Caution - prednisolone may cause adrenal suppression; sulfacetamide crosses placenta, theoretical risk of kernicterus. Overall: Use only if benefit outweighs risk; monitor for fetal growth restriction. |
| Fetal Monitoring | Monitor maternal blood pressure, glucose, and signs of infection. Fetal ultrasound for growth restriction. Neonatal assessment for adrenal suppression (if high-dose systemic prednisolone). |
| Fertility Effects | No known direct adverse effects on fertility. Chronic infections treated may impact fertility; condition itself may affect reproductive outcomes. |
| Clinical Pearls | PREDSULFAIR II is a fixed-dose combination of prednisolone and sulfacetamide. In ophthalmic infections, always rule out fungal or viral etiologies before initiating steroids; concurrent antiviral therapy may be needed for herpetic keratitis. Monitor intraocular pressure (IOP) in prolonged use (>10 days) due to steroid-induced glaucoma. Use with caution in patients with thin corneas as it may increase perforation risk. Shake suspension well before instillation to ensure uniform drug dispersion. |
| Patient Advice | Shake the bottle vigorously before each use. · Do not touch the dropper tip to any surface, including your eye, to avoid contamination. · Remove contact lenses before instillation and wait at least 15 minutes before reinserting. · Apply prescribed number of drops; avoid blinking or rubbing eyes after instillation. · Report any vision changes, eye pain, or increased redness immediately. · Complete full course as prescribed; do not stop abruptly even if symptoms improve. · May cause temporary blurred vision; avoid driving or operating machinery until clear. |